1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Busy 2021 Ahead For Almirall On Business And Clinical Fronts

Acquires Psoriasis Cream From MC2

 
• By Kevin Grogan

Gianfranco Nazzi will be taking over as head of the Spanish company shortly and the Barcelona-based firm's prospects look good as its dermatology portfolio and pipeline blossom.

Almirall headquarters
Big year for the Spanish group • Source: Archive

With a new CEO waiting in the wings and eagerly anticipated late-stage data coming soon on its atopic dermatitis candidate lebrikizumab, Almirall SA is shaping up for a pivotal year of growth.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

More from Therapy Areas